User profiles for LAURA MAGNANO
 | Laura MagnanoHospital Clínic de Barcelona Verified email at clinic.ub.es Cited by 1593 |
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international …
Background Patients with follicular lymphoma have heterogeneous outcomes. Predictor
models to distinguish, at diagnosis, between patients at high and low risk of progression are …
models to distinguish, at diagnosis, between patients at high and low risk of progression are …
[HTML][HTML] Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy
…, A Martínez-Trillos, E Giné, I Dlouhy, L Magnano… - Annals of …, 2015 - Springer
A retrospective study was performed to assess the outcome of patients with diffuse large B
cell lymphoma (DLBCL) who did not achieve complete response or who relapsed before and …
cell lymphoma (DLBCL) who did not achieve complete response or who relapsed before and …
Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study
Purpose: We analyzed the utility of cell-free DNA (cfDNA) in a prospective population-based
cohort to determine the mutational profile, assess tumor burden, and estimate its impact in …
cohort to determine the mutational profile, assess tumor burden, and estimate its impact in …
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO …
S Alonso‐Álvarez, L Magnano… - British journal of …, 2017 - Wiley Online Library
The diagnostic criteria for follicular lymphoma ( FL ) transformation vary among the largest
series, which commonly exclude histologically‐documented transformation ( HT ) mandatorily. …
series, which commonly exclude histologically‐documented transformation ( HT ) mandatorily. …
[HTML][HTML] The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
…, S Martin, C Capdevila, L Hernández, L Magnano… - Leukemia, 2021 - nature.com
Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival
with macrophages playing a controversial role. In the present study, using FL primary …
with macrophages playing a controversial role. In the present study, using FL primary …
Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era
A Rivas‐Delgado, L Magnano… - British journal of …, 2019 - Wiley Online Library
Follicular lymphoma ( FL ) is an indolent disease characterized by long survival but frequent
relapses. Before the introduction of rituximab, the clinical course of these patients showed a …
relapses. Before the introduction of rituximab, the clinical course of these patients showed a …
MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
…, A Martínez-Trillos, E Giné, I Dlouhy, L Magnano… - Clinical Cancer …, 2016 - AACR
Purpose: Mutations in MYD88 are found in different lymphoproliferative disorders associated
with particular biologic characteristics and clinical impact. The aim of this study was to …
with particular biologic characteristics and clinical impact. The aim of this study was to …
[HTML][HTML] Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter's transformation
…, O Balagué, N Martínez-Cibrián, L Magnano… - Frontiers in …, 2022 - frontiersin.org
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic
leukaemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated …
leukaemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated …
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
…, I Isola, A Pereira, MT Cibeira, L Magnano… - Leukemia, 2018 - nature.com
Smoldering multiple myeloma (SMM) is a biologically heterogeneous, clinically defined
entity with a variable rate of progression to symptomatic multiple myeloma (MM). Reliable …
entity with a variable rate of progression to symptomatic multiple myeloma (MM). Reliable …
[HTML][HTML] Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in …
Mutations in genes of the RAS-BRAF-MAPK-ERK pathway have not been fully explored in
patients with chronic lymphocytic leukemia. We, therefore, analyzed the clinical and biological …
patients with chronic lymphocytic leukemia. We, therefore, analyzed the clinical and biological …